Phibro Animal Health Corporation Declares Quarterly Dividend of $0.12 (NASDAQ:PAHC)

Phibro Animal Health Corporation (NASDAQ:PAHC) announced a quarterly dividend on Tuesday, May 5th. Shareholders of record on Wednesday, June 3rd will be given a dividend of 0.12 per share on Wednesday, June 24th. This represents a c) annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend is Wednesday, June 3rd.

Phibro Animal Health has a dividend payout ratio of 23.9% meaning its dividend is sufficiently covered by earnings. Analysts expect Phibro Animal Health to earn $3.28 per share next year, which means the company should continue to be able to cover its $0.48 annual dividend with an expected future payout ratio of 14.6%.

Phibro Animal Health Price Performance

NASDAQ PAHC opened at $56.88 on Wednesday. The firm’s 50 day moving average is $53.93 and its 200-day moving average is $46.34. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The company has a market capitalization of $2.31 billion, a PE ratio of 25.17, a price-to-earnings-growth ratio of 0.84 and a beta of 0.61. Phibro Animal Health has a 12-month low of $18.89 and a 12-month high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The firm had revenue of $373.91 million for the quarter, compared to analyst estimates of $355.64 million. Equities research analysts anticipate that Phibro Animal Health will post 3.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on PAHC. Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a research report on Friday, February 6th. Finally, Citigroup began coverage on Phibro Animal Health in a research note on Wednesday, April 15th. They set a “neutral” rating and a $62.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $42.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.